Celanese Corp director Michael Koenig reported routine equity compensation activity. On May 11, 2026, he acquired 2,975 shares of Common Stock as a grant/award of restricted stock units with no cash paid per share. According to the footnotes, these units were granted under the Company’s Amended and Restated 2018 Global Incentive Plan and will vest in full on the one-year anniversary of the grant date.
On May 9, 2026, 1,013 shares of Common Stock were disposed of at $57.51 per share to cover taxes due upon vesting and settlement of performance-based restricted stock units, a non-market tax-withholding transaction. After these transactions, Koenig directly holds 8,320 shares of Celanese common stock.
MOORTHY GANESH reported acquisition or exercise transactions in this Form 4 filing.
Celanese Corp director Ganesh Moorthy reported an annual equity compensation grant in the form of restricted stock units. He received 2,975 shares of Common Stock as a grant or award at a stated price of $0.00 per share under the company’s Amended and Restated 2018 Global Incentive Plan. These restricted stock units vest in full on the one-year anniversary of the grant date, meaning the shares become fully owned after that period. Following this award, Moorthy directly holds 8,990 shares of Celanese common stock and indirectly holds 3,000 shares through the Ganesh and Hema Moorthy Revocable Living Trust. This filing reflects routine director compensation rather than an open-market purchase or sale.
Celanese Corp director Deborah J. Kissire reported compensation-related equity movements. On May 9, 2026, 3,376 Restricted Stock Units vested, and she deferred the resulting 3,376 shares of Common Stock into 3,376 shares of phantom stock under the company’s 2008 Deferred Compensation Plan, leaving 1,100 Common shares directly held.
On May 11, 2026, she received an annual grant of 2,975 restricted stock units under the Amended and Restated 2018 Global Incentive Plan, which vest in full one year after grant. She also received 2.984 additional phantom stock shares as dividend equivalents, bringing her phantom stock balance to 9,303.777 units, each representing the right to receive one share of Common Stock.
Celanese Corp director Kim K.W. Rucker reported routine equity compensation and deferral activity. On May 9, 2026, 3,376 Restricted Stock Units vested and were exchanged for 3,376 shares of phantom stock under the company’s 2008 Deferred Compensation Plan, in place of receiving common shares.
On the same date, the director’s common stock position decreased by 3,376 shares to reflect this deferral, while the phantom stock balance increased by the same amount. On May 11, 2026, the director received an annual grant of 2,975 restricted stock units in common stock and an additional 4.796 shares of phantom stock as dividend equivalents.
After these transactions, the director directly holds 3,031 shares of Celanese common stock and 12,900.519 shares of phantom stock, each phantom share representing the right to receive one share of common stock in the future. These are compensation and deferral arrangements rather than open-market stock purchases or sales.
Celanese Corp director Kathryn Hill received new equity-based compensation on May 11, 2026. She was granted 2,975 shares of Common Stock in the form of restricted stock units under the company’s Amended and Restated 2018 Global Incentive Plan, which vest in full one year after the grant date. Following this award, she directly holds 19,783.48 shares of Common Stock.
Hill also acquired 0.575 shares of phantom stock as dividend equivalents on compensation deferred under the company’s 2008 Deferred Compensation Plan. Each phantom share represents the right to receive one share of Common Stock, bringing her phantom stock balance to 1,141.769 units. These are compensation-related grants, not open‑market purchases.
Celanese Corp director Christopher J. Kuehn reported equity compensation and a deferral election, not open-market trading. On May 11, he received 2,975 shares of Common Stock as a grant with a reported price of $0.00 per share, leaving him with 2,975 Common shares directly owned.
On May 9, 3,376 Restricted Stock Units vested, and instead of taking delivery of 3,376 Common shares, he exchanged them for 3,376 shares of phantom stock under Celanese’s 2008 Deferred Compensation Plan. Each phantom stock share represents the right to receive one Common share, payable in stock at a later date or upon his termination as a director.
Celanese Corp director Edward G. Galante received new equity-based compensation. On May 11, 2026, he was granted 4,676 shares of Common Stock in the form of restricted stock units under the Amended and Restated 2018 Global Incentive Plan. These units vest in full on the one-year anniversary of the grant date.
He also acquired 3.429 shares of phantom stock as dividend equivalents on deferred compensation under the 2008 Deferred Compensation Plan. Each phantom stock unit represents the right to receive one share of Common Stock and becomes payable in shares after his service as a director ends. Following these awards, he directly holds 26,053 shares of Common Stock and 6,810.222 phantom stock units.
Norges Bank reports passive ownership of common stock of Celanese Corp. The filing states 6,924,205 shares beneficially owned, equal to 6.1866% of the class as of 03/31/2026. The filing lists sole voting power of 6,814,855 shares and shared dispositive power of 109,350.
Celanese Corporation reported improved profitability for the three months ended March 31, 2026. Net sales were $2,337 million, slightly below $2,389 million a year earlier, but operating profit rose to $214 million from $165 million as mix and one‑time items helped margins.
Net earnings attributable to Celanese were $44 million, compared with a loss of $24 million, and diluted earnings per share moved to $0.40 from a loss of $0.22. Results benefited from a $50 million gain on the sale of the Micromax business and higher equity earnings, partially offset by $20 million of restructuring charges and higher interest expense of $183 million.
Operating cash flow increased to $76 million, while investing inflows of $425 million were driven by $493 million of proceeds from the Micromax divestiture. Cash and cash equivalents rose to $1,758 million and long-term debt including current installments stood at $12,599 million, reflecting a leveraged but liquid balance sheet.
Celanese Corporation reported first quarter 2026 adjusted earnings per share of $0.85, reflecting solid execution in a weak demand environment. Engineered Materials delivered adjusted EBIT of $220 million and operating EBITDA of $324 million, helped by favorable mix, cost reductions and value‑based pricing.
The Acetyl Chain generated adjusted EBIT of $131 million and operating EBITDA of $194 million, with late‑quarter supply disruptions creating high‑value pricing opportunities that are expected to benefit second quarter results. Company‑wide free cash flow was $3 million, an improvement versus typical seasonal cash use.
Management raised its full‑year 2026 free cash flow target to $700–$800 million and continues to prioritize deleveraging, with net debt of $10.8 billion at quarter‑end and plans to repay roughly $900 million of bonds in the second and third quarters. For the second quarter, Celanese guides to adjusted EPS of $2.00–$2.40, driven primarily by stronger Acetyl Chain earnings, and expects second quarter to be the highest‑earning quarter of 2026.